Officials indicated that it was difficult to discuss the copyright chapter without the return of Bill C-32. Once a bill is tabled, they expect talks on the issue to accelerate. In addition to the substantive provisions found in C-32, the EU is also focused on enforcement-related provisions. Officials indicated that the EU demands will likely be similar to those found in the Anti-Counterfeiting Trade Agreement. They acknowledged that new legislation will needed to comply with these treaties, suggesting that a second copyright bill focused on enforcement (including new border measures provisions) will quickly follow the C-32 bill. On the patent front, the large brand name pharmaceutical companies are supporting further change to Canadian law, while the generic pharmaceutical companies oppose reforms. The issue is a big priority for the EU, but no progress was made to resolve the stalemate.